ASSESSMENT OF ADHERENCE IN OUTPATIENTS WITH OPEN-ANGLE GLAUCOMA
Abstract
Glaucoma is chronic, progressive optic nerve neuropathy that leads to permanent defects of the visual field. Glaucoma still cannot be cured, however, with proper and correct use of prescribed therapy, it can be managed in a way to slow its progression and consequent loss of vision. Thus, having good adherence to recommended medications is of utmost importance for glaucoma patients.
The study aimed to assess the degree of adherence to prescribed therapy for open-angle glaucoma in outpatients.
In February 2019, one-month research was done at the Glaucoma Department of the Eye Clinic, Clinical Center Niši. It was performed on 77 outpatients using an anonymous, volunteer-based questionnaire consisting of 11 questions related to demographic and socioeconomic characteristics, disease duration, as well as adherence to recommended therapy and reasons for possible non-adherence.
Out of the total outpatient number interviewed, 62.34% stated that they took their therapy as recommended, and 37.66% stated doing it not so regularly. Among those who were not taking therapy regularly, more were patients of older age (p = 0.00001; p < 0.05). No difference related to gender was found. Patients on multidrug glaucoma therapy were less adherent than those who used only one drug (p = 0.00034; p < 0.05). Better adherence was found in patients without comorbidities (87.5%) compared to those with some concomitant disease (35.14%), there was a statistically relevant correlation between these two parameters (p = 0.000002; p < 0.005). The most common reasons for non-adherence were adverse drug effects (100%), very long treatment period (89.66%) and patient’s forgetfulness.
Relatively high, but not absolutely adequate degree of adherence is present among open-angle outpatients. Improvement of adherence can be achieved with optimal choice of therapeutic regimen, prescription of drugs with milder adverse effects, patient education about the course of disease and its possible consequences, i.e. blindness, as well as with emphasizing the importance of following recommended pharmacotherapeutic measures.
References
Bjelović N, Senćanić I, Trajković G. Značaj prihvatanja terapije u lečenju pacijenata sa glaukomom. Acta chirurgica iugoslavica 2014;61(4):47-53.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296-310. [CrossRef][PubMed]
Đurić D, Mitrović M, Jovanović D, Jovanović Z, Pavlović I, Milovanović O, et al. Komplijansa, adherenca, konkordanca i perzistenca u savremenoj farmakoterapiji. Medicinski časopis 2012;46(4):205-13.
Friedman DS, Quigley HA, Gelb L, Tan J, Margolis J, Shah SN, et al. Using pharmacy claims data to study adherence to glaucoma medications: Methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Investigate Ophthalmology & Visual Science 2007;48:5052-7. [CrossRef][PubMed]
Jordanova E, Hentova Senćanić P, Marjanović I, Senćanić I, Stefanović I, Baralić M. Uticaj centralne debljine rožnjače na vrednosti intraokularno pritiska izmerenog dvema metodama - Goldmanovom aplanacionom i dinamičkom konturnom tonometrijom kod ispitanika sa dijagnozom primarnog glaukoma otvorenog ugla . Halo 194 2020;26(1):7-14. [CrossRef]
Okeke CO, Quigley HA, Jampel HD, Ying GS, Plyler RJ, Jiang Y, et al. Adherence with Topical Glaucoma Medication Monitored Electronically: The Travatan Dosing Aid Study. Ophthalmology 2009;116:191–9. [CrossRef][PubMed]
Olthoff CM, Hoevenaars JG, van der Borne BW, Webers CA, Schouten JS. Prevalence and determinants of non-adherence to topical hypotensive treatment in Dutch glaucoma patients. Graefes Arch Clin Exp Ophthalmol 2009;247:235-43. [CrossRef][PubMed]
Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with Ocular Hypotensive Treatment in Patients with Glaucoma or Ocular Hypertension: An Evidence-Based Review. Ophthalmology 2005;112:953–61. [CrossRef][PubMed]
Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian Journal of Ophthalmology 2011;59(7):93-6. [CrossRef][PubMed]
Robin AL, Covert D. Does Adjunctive Glaucoma Therapy Affect Adherence to the Initial Primary Therapy?. Ophthalmology 2005;112:863–8. [CrossRef][PubMed]
Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol 2008;53(Suppl 1):S57-S68. [CrossRef][PubMed]
Schwartz GF. Compliance and persistency in glaucoma follow-up treatment. Curr Opin Ophthalmol 2005;16(2):114-21. [CrossRef][PubMed]
Stewart WC, Konstas AG, Pfeiffer N. Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. J Ocul Pharmacol Ther 2004;20(6):461-9. [CrossRef][PubMed]
Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res 2011;36(5):391-8. [CrossRef][PubMed]
Vandenbroeck S, De Geest S, Zeyen T, Stalmans I, Dobbels F. Patient-reported outcomes (PRO's) in glaucoma: a systematic review. Eye (Lond) 2011;25(5):555-77. [CrossRef][PubMed]
Winfield AJ, Jessiman D, Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol 1990;74:477-80. [CrossRef][PubMed]
